<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:26:48Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6516109" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6516109</identifier>
        <datestamp>2019-06-20</datestamp>
        <setSpec>oncologist</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Oncologist</journal-id>
              <journal-id journal-id-type="iso-abbrev">Oncologist</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id>
              <journal-id journal-id-type="publisher-id">The Oncologist</journal-id>
              <journal-id journal-id-type="pmc">oncologist</journal-id>
              <journal-id journal-id-type="hwp">theoncologist</journal-id>
              <journal-title-group>
                <journal-title>The Oncologist</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1083-7159</issn>
              <issn pub-type="epub">1549-490X</issn>
              <publisher>
                <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
                <publisher-loc>Hoboken, USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6516109</article-id>
              <article-id pub-id-type="pmcid">PMC6516109</article-id>
              <article-id pub-id-type="pmc-uid">6516109</article-id>
              <article-id pub-id-type="pmid">30679315</article-id>
              <article-id pub-id-type="pmid">30679315</article-id>
              <article-id pub-id-type="doi">10.1634/theoncologist.2018-0878</article-id>
              <article-id pub-id-type="publisher-id">ONCO12812</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>4</subject>
                  <subject>6</subject>
                  <subject>31</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Trial Results</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)</article-title>
              </title-group>
              <contrib-group>
                <contrib id="onco12812-cr-0001" contrib-type="author">
                  <name>
                    <surname>Halfdanarson</surname>
                    <given-names>Thorvardur R.</given-names>
                  </name>
                  <xref ref-type="correspondence-address" rid="correspondenceTo">*</xref>
                  <xref ref-type="aff" rid="onco12812-aff-0001">
                    <sup>a</sup>
                  </xref>
                  <address>
                    <email>halfdanarson.thorvardur@mayo.edu</email>
                  </address>
                </contrib>
                <contrib id="onco12812-cr-0002" contrib-type="author">
                  <name>
                    <surname>Foster</surname>
                    <given-names>Nathan R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12812-aff-0002">
                    <sup>b</sup>
                  </xref>
                  <xref ref-type="aff" rid="onco12812-aff-0003">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib id="onco12812-cr-0003" contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>George P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12812-aff-0006">
                    <sup>f</sup>
                  </xref>
                </contrib>
                <contrib id="onco12812-cr-0004" contrib-type="author">
                  <name>
                    <surname>Meyers</surname>
                    <given-names>Jeffrey P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12812-aff-0003">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib id="onco12812-cr-0005" contrib-type="author">
                  <name>
                    <surname>Smyrk</surname>
                    <given-names>Thomas C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12812-aff-0004">
                    <sup>d</sup>
                  </xref>
                </contrib>
                <contrib id="onco12812-cr-0006" contrib-type="author">
                  <name>
                    <surname>McCullough</surname>
                    <given-names>Ann E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12812-aff-0007">
                    <sup>g</sup>
                  </xref>
                </contrib>
                <contrib id="onco12812-cr-0007" contrib-type="author">
                  <name>
                    <surname>Ames</surname>
                    <given-names>Matthew M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12812-aff-0005">
                    <sup>e</sup>
                  </xref>
                </contrib>
                <contrib id="onco12812-cr-0008" contrib-type="author">
                  <name>
                    <surname>Jaffe</surname>
                    <given-names>Jeffrry P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12812-aff-0008">
                    <sup>h</sup>
                  </xref>
                </contrib>
                <contrib id="onco12812-cr-0009" contrib-type="author">
                  <name>
                    <surname>Alberts</surname>
                    <given-names>Steven R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="onco12812-aff-0001">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <aff id="onco12812-aff-0001"><label><sup>a</sup></label><institution>Division of Medical Oncology, Mayo Clinic</institution>, <city>Rochester</city>, <state>Minnesota</state>, <country country="US">USA</country></aff>
                <aff id="onco12812-aff-0002"><label><sup>b</sup></label><institution>Division of Biomedical Statistics and Informatics, Mayo Clinic</institution>, <city>Rochester</city>, <state>Minnesota</state>, <country country="US">USA</country></aff>
                <aff id="onco12812-aff-0003"><label><sup>c</sup></label><institution>Alliance Statistics and Data Center, Mayo Clinic</institution>, <city>Rochester</city>, <state>Minnesota</state>, <country country="US">USA</country></aff>
                <aff id="onco12812-aff-0004"><label><sup>d</sup></label><institution>Department of Pathology and Laboratory Medicine, Mayo Clinic</institution>, <city>Rochester</city>, <state>Minnesota</state>, <country country="US">USA</country></aff>
                <aff id="onco12812-aff-0005"><label><sup>e</sup></label><institution>Department of Oncology, Mayo Clinic</institution>, <city>Rochester</city>, <state>Minnesota</state>, <country country="US">USA</country></aff>
                <aff id="onco12812-aff-0006"><label><sup>f</sup></label><institution>Mayo Clinic</institution>, <city>Jacksonville</city>, <state>Florida</state>, <country country="US">USA</country></aff>
                <aff id="onco12812-aff-0007"><label><sup>g</sup></label><institution>Department of Pathology and Laboratory Medicine, Mayo Clinic</institution>, <city>Scottsdale</city>, <state>Arizona</state>, <country country="US">USA</country></aff>
                <aff id="onco12812-aff-0008"><label><sup>h</sup></label><institution>Metro‐Minnesota Community Oncology Research Consortium</institution>, <city>Saint Louis Park</city>, <state>Minnesota</state>, <country country="US">USA</country></aff>
              </contrib-group>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>Correspondence: Thorvardur R. Halfdanarson, M.D., Division of Medical Oncology, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55905, USA. Telephone: 319‐400‐2181; e‐mail: <email>halfdanarson.thorvardur@mayo.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>1</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>5</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>24</day>
                <month>1</month>
                <year>2019</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
              <volume>24</volume>
              <issue>5</issue>
              <issue-id pub-id-type="doi">10.1002/onco.v24.5</issue-id>
              <fpage>589</fpage>
              <lpage>e160</lpage>
              <history>
                <date date-type="received">
                  <day>19</day>
                  <month>11</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>13</day>
                  <month>12</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement content-type="article-copyright">© AlphaMed Press; the data published online to support this summary are the property of the authors</copyright-statement>
              </permissions>
              <self-uri content-type="pdf" xlink:href="onco12812.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="onco12812-sec-0001">
                  <title>Lessons Learned.</title>
                  <p>
                    <list list-type="bullet" id="onco12812-list-0001">
                      <list-item id="onco12812-li-0001">
                        <p>Dual epidermal growth factor receptor (EGFR)‐directed therapy with erlotinib and panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the clinical relevance is uncertain given the limited role of gemcitabine monotherapy.</p>
                      </list-item>
                      <list-item id="onco12812-li-0002">
                        <p>A significantly longer overall survival was observed in patients receiving the dual EGFR‐directed therapy.</p>
                      </list-item>
                      <list-item id="onco12812-li-0003">
                        <p>The dual EGFR‐directed therapy resulted in increased toxicity.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
                <sec id="onco12812-sec-0002">
                  <title>Background.</title>
                  <p>Gemcitabine is active in patients with advanced pancreatic adenocarcinoma. The combination of erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, and gemcitabine was shown to modestly prolong overall survival when compared with gemcitabine alone. The North Central Cancer Treatment Group (now part of Alliance for Clinical Trials in Oncology) trial N064B compared gemcitabine plus erlotinib versus gemcitabine plus combined EGFR inhibition with erlotinib and panitumumab.</p>
                </sec>
                <sec id="onco12812-sec-0003">
                  <title>Methods.</title>
                  <p>Eligible patients with metastatic adenocarcinoma of the pancreas were randomized to either gemcitabine 1,000 mg/m<sup>2</sup> on days 1, 8, and 15 of a 28‐day cycle with erlotinib 100 mg p.o. daily (Arm A) or the same combination with the addition of panitumumab 4 mg/kg on days 1 and 15 of a 28‐day cycle (Arm B). The primary endpoint of the trial was overall survival. Secondary endpoints included progression‐free survival, the confirmed response rate, and toxicity. Comparison between arms for the primary endpoint was done with a one‐sided log‐rank test, and a <italic>p</italic> value less than .20 was considered statistically significant. Response rate comparison was done with Fisher's exact test. All other reported <italic>p</italic> values are two‐sided.</p>
                </sec>
                <sec id="onco12812-sec-0004">
                  <title>Results.</title>
                  <p>A total of 92 patients were randomized, 46 to each arm. The median overall survival was 4.2 months in Arm A and 8.3 months in Arm B (hazard ratio, 0.817; 95% confidence interval [CI], 0.530–1.260; <italic>p</italic> = .1792). The progression‐free survival was 2.0 months in Arm A and 3.6 months in Arm B (hazard ratio, 0.843; 95% CI, 0.555–1.280; <italic>p</italic> = .4190). A partial confirmed response was seen in 8.7% of patients on Arm A and 6.5% on Arm B (<italic>p</italic> = .9999). No patients had a complete response. Grade 3 and higher nonhematologic toxicities were more common in patients on Arm B compared with those on Arm A (82.6% vs. 52.2%; <italic>p</italic> = .0018).</p>
                </sec>
                <sec id="onco12812-sec-0005">
                  <title>Conclusion.</title>
                  <p>Dual EGFR‐directed therapy resulted in a significant prolongation of overall survival in patients with advanced adenocarcinoma of the pancreas but was associated with substantially increased toxicities. Dual EGFR‐directed therapy in combination with gemcitabine alone cannot be recommended for further study, as single‐agent gemcitabine is no longer considered an appropriate therapy for otherwise fit patients with metastatic pancreatic cancer.</p>
                </sec>
              </abstract>
              <trans-abstract xml:lang="zh" abstract-type="main">
                <p xml:lang="zh">经验获取</p>
                <p xml:lang="zh">• 使用厄洛替尼和帕尼单抗联合吉西他滨的表皮生长因子受体 (EGFR) 双重拮抗定向治疗优于吉西他滨和厄洛替尼，但由于吉西他滨单药治疗的作用有限，临床相关性尚不明确。</p>
                <p xml:lang="zh">• 观察到接受 EGFR 双重拮抗定向治疗的患者的总生存期明显延长。</p>
                <p xml:lang="zh">• EGFR 双重拮抗定向治疗导致毒性增加。</p>
                <p xml:lang="zh">摘要</p>
                <p xml:lang="zh"><bold><italic>背景。</italic></bold>吉西他滨对晚期胰腺癌患者有效。与单用吉西他滨相比，厄洛替尼，一种口服表皮生长因子受体 (EGFR) 抑制剂，和吉西他滨的联合用药稍微延长总生存期。中北癌症治疗组(现为肿瘤临床试验联盟的一部分)N064B试验比较了吉西他滨联合厄洛替尼对比吉西他滨加厄洛替尼和帕尼单抗联合进行 EGFR 抑制的疗效。</p>
                <p xml:lang="zh"><bold><italic>方法。</italic></bold>患有转移性胰腺癌的入组患者随机分配至吉西他滨(1,000 mg/m <sup>2</sup>， 在第 1、8 和 15 天用药，28 天为一周期)联合厄洛替尼(100 mg，每天口服)(A 组)或分配至同样联合用药再加上帕尼单抗(4 mg/kg，在第 1 天和第 15 天用药，28 天为一周期)(B 组)。该试验的主要终点为总生存期。次要终点包括无进展生存期、确诊的缓解率和毒性。使用单侧对数秩检验进行各组之间主要终点的比较，并且 p 值小于 0.20 被认为具有统计学显著性意义。用 Fisher 精确检验进行缓解率比较。所有其他报告的 p 值都是双侧的。</p>
                <p xml:lang="zh"><bold><italic>结果。</italic></bold>共有 92 名患者随机分组，每组 46 名患者。A 组的中位总生存期为 4.2 个月，B 组为 8.3 个月 [风险比，0.817；95% 置信区间 (CI)，0.530‐1.260；<italic>p</italic> = 0.179 2]。A 组的无进展生存期为 2.0 个月，B 组为 3.6 个月(风险比，0.843；95% CI，0.555‐1.280；<italic>p</italic> = 0.419 0)。A 组有 8.7% 的患者出现了部分确认的缓解，而 B 组则为 6.5%(<italic>p</italic> = 0.999 9)。没有患者出现完全缓解。3 级或以上的非血液学毒性在 B 组患者中比在 A 组患者更常见(82.6 % vs. 52.2%；<italic>p</italic> = 0.001 8)。</p>
                <p xml:lang="zh"><bold><italic>结论。</italic></bold>EGFR 双重拮抗定向治疗可使晚期胰腺癌患者的总生存期显著延长，但与毒性显著增加有关联。不推荐将 EGFR 双重拮抗定向治疗与单药吉西他滨用于进一步研究，因为单药吉西他滨不再被认为是其他适合的转移性胰腺癌患者的恰当治疗方法。</p>
              </trans-abstract>
              <counts>
                <page-count count="9"/>
              </counts>
            </article-meta>
          </front>
          <body id="onco12812-body-0001">
            <sec sec-type="discussion" id="onco12812-sec-0006">
              <title>Discussion</title>
              <p>Single‐agent gemcitabine has modest activity in patients with advanced adenocarcinoma of the pancreas. Gemcitabine was shown to be superior to 5‐fluorouracil with an improvement in a composite endpoint of pain, performance status, and weight (clinical benefit response) and a modest prolongation of overall survival [<xref rid="onco12812-bib-0001" ref-type="ref">1</xref>]. Multiple trials have compared gemcitabine alone with combinations of gemcitabine and both cytotoxic and molecularly targeted drugs and failed to show improvement over gemcitabine alone. A large trial conducted by the National Cancer Institute of Canada compared gemcitabine with and without erlotinib in patients with locally advanced or metastatic pancreatic cancer. The overall survival (OS) in the combination arm was statistically superior to the gemcitabine alone arm (6.2 months vs. 5.9 months), but the increase in the overall survival was of questionable clinical importance [<xref rid="onco12812-bib-0002" ref-type="ref">2</xref>]. Another large trial compared gemcitabine monotherapy with the combination of gemcitabine and cetuximab [<xref rid="onco12812-bib-0003" ref-type="ref">3</xref>]. Although the combination resulted in a slightly longer overall survival (5.9 months vs. 6.3 months), the difference was not statistically different. Given evidence from preclinical and translational studies suggesting synergistic efficacy of different classes of anti‐EGFR agents, this trial was performed [<xref rid="onco12812-bib-0004" ref-type="ref">4</xref>], [<xref rid="onco12812-bib-0005" ref-type="ref">5</xref>].</p>
              <p>Designed as a randomized phase II trial, evaluating the efficacy of a combined EGFR inhibition using erlotinib and panitumumab in conjunction with gemcitabine with gemcitabine plus erlotinib as a reference arm, 92 patients were enrolled, 46 on each arm. The patient characteristics were balanced between the arms. The primary endpoint was OS, with progression‐free survival (PFS), radiographic response rate, and toxicity as secondary endpoints. The trial was designed to detect with 80% power a difference in the primary outcome between arms using a one‐sided log‐rank test with an α of .20. A <italic>p</italic> value less than .20 was therefore considered significant for OS.</p>
              <p>The median OS was longer in the combined EGFR inhibition plus gemcitabine arm (Arm B) compared with gemcitabine with erlotinib (Arm A)—8.3 months versus 4.2 months—and met statistical significance (hazard ratio, 0.817; 95% CI, 0.530–1.260; <italic>p</italic> = .1792) (Fig. <xref rid="onco12812-fig-0001" ref-type="fig">1</xref>). A nonsignificant difference in the PFS was seen, favoring Arm B (median: 3.6 months in Arm B and 2.0 months in Arm A; hazard ratio 0.843; 95% CI, 0.555–1.280; <italic>p</italic> = .4190) (Fig. <xref rid="onco12812-fig-0002" ref-type="fig">2</xref>). A partial response was seen in 8.7% of patients on Arm A and 6.5% on Arm B (<italic>p</italic> = .9999). No patients had a complete response. Grade 3 and higher nonhematologic toxicities were more common in patients receiving combined EGFR inhibition therapy (82.6% vs. 52.2%; <italic>p</italic> = .0018).</p>
              <fig fig-type="Figure" xml:lang="en" id="onco12812-fig-0001" orientation="portrait" position="float">
                <label>Figure 1.</label>
                <caption>
                  <p>Overall survival by treatment arm.</p>
                  <p>Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Gem, gemcitabine.</p>
                </caption>
                <graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12812-fig-0001">
                  <alt-text>image</alt-text>
                </graphic>
              </fig>
            </sec>
            <sec id="onco12812-sec-0007">
              <title>Trial Information</title>
              <p>
                <def-list list-type="simple" id="onco12812-lp-0001">
                  <def-item>
                    <term id="onco12812-li-0004">Disease</term>
                    <def id="onco12812-li-0005">
                      <p>Pancreatic cancer</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0006">Stage of Disease/Treatment</term>
                    <def id="onco12812-li-0007">
                      <p>Metastatic/advanced</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0008">Prior Therapy</term>
                    <def id="onco12812-li-0009">
                      <p>None</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0010">Type of Study ‐ 1</term>
                    <def id="onco12812-li-0011">
                      <p>Phase II</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0012">Type of Study ‐ 2</term>
                    <def id="onco12812-li-0013">
                      <p>Randomized</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0014">Primary Endpoint</term>
                    <def id="onco12812-li-0015">
                      <p>Overall survival</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0016">Secondary Endpoint</term>
                    <def id="onco12812-li-0017">
                      <p>Progression‐free survival</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0018">Secondary Endpoint</term>
                    <def id="onco12812-li-0019">
                      <p>Overall response rate</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0020">Secondary Endpoint</term>
                    <def id="onco12812-li-0021">
                      <p>Toxicity</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0022">Additional Details of Endpoints or Study Design</term>
                    <def id="onco12812-li-0023">
                      <p>The trial was opened on December 30, 2009 and was closed to accrual on August 13, 2010. Trial information and patient characteristics are summarized in Table <xref rid="onco12812-tbl-0001" ref-type="table">1</xref>.</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0026">Investigator's Analysis</term>
                    <def id="onco12812-li-0027">
                      <p>Level of activity did not meet planned endpoint.</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12812-sec-0008">
              <title>Drug Information (Control – Arm A)</title>
              <p>
                <def-list list-type="simple" id="onco12812-lp-0002">
                  <def-item>
                    <term id="onco12812-li-0028">Drug 1</term>
                    <def id="onco12812-li-0029">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0030"> <bold>Generic/Working Name</bold></term>
                    <def id="onco12812-li-0031">
                      <p>Gemcitabine</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0032"> <bold>Drug Class</bold></term>
                    <def id="onco12812-li-0033">
                      <p>Antimetabolite</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0034"> <bold>Dose</bold></term>
                    <def id="onco12812-li-0035">
                      <p>1,000 milligrams (mg) per squared meter (m<sup>2</sup>)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0036"> <bold>Route</bold></term>
                    <def id="onco12812-li-0037">
                      <p>IV</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0038"> <bold>Schedule of Administration</bold></term>
                    <def id="onco12812-li-0039">
                      <p>On days 1, 8, and 15 of a 28‐day cycle</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0040">Drug 2</term>
                    <def id="onco12812-li-0041">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0042"> <bold>Generic/Working Name</bold></term>
                    <def id="onco12812-li-0043">
                      <p>Erlotinib</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0044"> <bold>Drug Class</bold></term>
                    <def id="onco12812-li-0045">
                      <p>EGFR</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0046"> <bold>Dose</bold></term>
                    <def id="onco12812-li-0047">
                      <p>100 milligrams (mg)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0048"> <bold>Route</bold></term>
                    <def id="onco12812-li-0049">
                      <p>Oral (p.o.)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0050"> <bold>Schedule of Administration</bold></term>
                    <def id="onco12812-li-0051">
                      <p>Daily</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12812-sec-0009">
              <title>Drug Information (Experimental – Arm B)</title>
              <p>
                <def-list list-type="simple" id="onco12812-lp-0003">
                  <def-item>
                    <term id="onco12812-li-0052">Drug 1</term>
                    <def id="onco12812-li-0053">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0054"> <bold>Generic/Working Name</bold></term>
                    <def id="onco12812-li-0055">
                      <p>Gemcitabine</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0056"> <bold>Drug Class</bold></term>
                    <def id="onco12812-li-0057">
                      <p>Antimetabolite</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0058"> <bold>Dose</bold></term>
                    <def id="onco12812-li-0059">
                      <p>1,000 milligrams (mg) per squared meter (m<sup>2</sup>)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0060"> <bold>Route</bold></term>
                    <def id="onco12812-li-0061">
                      <p>IV</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0062"> <bold>Schedule of Administration</bold></term>
                    <def id="onco12812-li-0063">
                      <p>On days 1, 8, and 15 of a 28‐day cycle</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0064">Drug 2</term>
                    <def id="onco12812-li-0065">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0066"> <bold>Generic/Working Name</bold></term>
                    <def id="onco12812-li-0067">
                      <p>Erlotinib</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0068"> <bold>Drug Class</bold></term>
                    <def id="onco12812-li-0069">
                      <p>EGFR</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0070"> <bold>Dose</bold></term>
                    <def id="onco12812-li-0071">
                      <p>100 milligrams (mg)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0072"> <bold>Route</bold></term>
                    <def id="onco12812-li-0073">
                      <p>Oral (p.o.)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0074"> <bold>Schedule of Administration</bold></term>
                    <def id="onco12812-li-0075">
                      <p>Daily</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0076">Drug 3</term>
                    <def id="onco12812-li-0077">
                      <p> </p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0078"> <bold>Generic/Working Name</bold></term>
                    <def id="onco12812-li-0079">
                      <p>Panitumumab</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0080"> <bold>Drug Class</bold></term>
                    <def id="onco12812-li-0081">
                      <p>EGFR</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0082"> <bold>Dose</bold></term>
                    <def id="onco12812-li-0083">
                      <p>4 milligrams (mg) per kilogram (kg)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0084"> <bold>Route</bold></term>
                    <def id="onco12812-li-0085">
                      <p>IV</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0086"> <bold>Schedule of Administration</bold></term>
                    <def id="onco12812-li-0087">
                      <p>On days 1 and 15 of a 28‐day cycle</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12812-sec-0010">
              <title>Patient Characteristics (Control – Arm A)</title>
              <p>
                <def-list list-type="simple" id="onco12812-lp-0004">
                  <def-item>
                    <term id="onco12812-li-0088">Number of Patients, Male</term>
                    <def id="onco12812-li-0089">
                      <p>29</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0090">Number of Patients, Female</term>
                    <def id="onco12812-li-0091">
                      <p>17</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0092">Stage</term>
                    <def id="onco12812-li-0093">
                      <p>Metastatic</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0094">Age</term>
                    <def id="onco12812-li-0095">
                      <p>Median (range): 60.5 years</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0096">Number of Prior Systemic Therapies</term>
                    <def id="onco12812-li-0097">
                      <p>Median (range): 0</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0098">Performance Status: ECOG</term>
                    <def id="onco12812-li-0099">
                      <p>0 — 52.2%</p>
                      <p>1 — 47.8%</p>
                      <p>2 —</p>
                      <p>3 —</p>
                      <p>Unknown —</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0100">Cancer Types or Histologic Subtypes</term>
                    <def id="onco12812-li-0101">
                      <p>Adenocarcinoma, 46</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12812-sec-0011">
              <title>Patient Characteristics (Experimental – Arm B)</title>
              <p>
                <def-list list-type="simple" id="onco12812-lp-0005">
                  <def-item>
                    <term id="onco12812-li-0102">Number of Patients, Male</term>
                    <def id="onco12812-li-0103">
                      <p>31</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0104">Number of Patients, Female</term>
                    <def id="onco12812-li-0105">
                      <p>15</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0106">Stage</term>
                    <def id="onco12812-li-0107">
                      <p>Metastatic</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0108">Age</term>
                    <def id="onco12812-li-0109">
                      <p>Median (range): 62 years</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0110">Number of Prior Systemic Therapies</term>
                    <def id="onco12812-li-0111">
                      <p>Median (range): 0</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0112">Performance Status: ECOG</term>
                    <def id="onco12812-li-0113">
                      <p>0 — 50%</p>
                      <p>1 — 50%</p>
                      <p>2 —</p>
                      <p>3 —</p>
                      <p>Unknown —</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0114">Cancer Types or Histologic Subtypes</term>
                    <def id="onco12812-li-0115">
                      <p>Adenocarcinoma, 46</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12812-sec-0012">
              <title>Primary Assessment Method (Control – Arm A)</title>
              <p>
                <def-list list-type="simple" id="onco12812-lp-0006">
                  <def-item>
                    <term id="onco12812-li-0116">Title</term>
                    <def id="onco12812-li-0117">
                      <p>Gemcitabine/Erlotinib</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0118">Number of Patients Enrolled</term>
                    <def id="onco12812-li-0119">
                      <p>46</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0120">Number of Patients Evaluable for Toxicity</term>
                    <def id="onco12812-li-0121">
                      <p>46</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0122">Number of Patients Evaluated for Efficacy</term>
                    <def id="onco12812-li-0123">
                      <p>46</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0124">Evaluation Method</term>
                    <def id="onco12812-li-0125">
                      <p>RECIST 1.0</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0126">Response Assessment – CR</term>
                    <def id="onco12812-li-0127">
                      <p><italic>n</italic> = 0 (0%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0128">Response Assessment – PR</term>
                    <def id="onco12812-li-0129">
                      <p><italic>n</italic> = 5 (10.9%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0130">Response Assessment – SD</term>
                    <def id="onco12812-li-0131">
                      <p><italic>n</italic> = 15 (32.5%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0132">Response Assessment – PD</term>
                    <def id="onco12812-li-0133">
                      <p><italic>n</italic> = 25 (54.3%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0134">Response Assessment – Other</term>
                    <def id="onco12812-li-0135">
                      <p><italic>n</italic> = 1 (2.2%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0136">(Median) Duration Assessments – PFS</term>
                    <def id="onco12812-li-0137">
                      <p>2 months; 95% CI, 1.8–3.3 months</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0138">(Median) Duration Assessments – OS</term>
                    <def id="onco12812-li-0139">
                      <p>4.2 months; 95% CI, 3.5–7.8 months</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0140">Outcome Notes</term>
                    <def id="onco12812-li-0141">
                      <p>Outcomes are summarized in Table <xref rid="onco12812-tbl-0002" ref-type="table">2</xref>.</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12812-sec-0013">
              <title>Primary Assessment Method for Phase II Experimental</title>
              <p>
                <def-list list-type="simple" id="onco12812-lp-0007">
                  <def-item>
                    <term id="onco12812-li-0142">Title</term>
                    <def id="onco12812-li-0143">
                      <p>Gemcitabine/Erlotinib/Panitumumab</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0144">Number of Patients Enrolled</term>
                    <def id="onco12812-li-0145">
                      <p>46</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0146">Number of Patients Evaluable for Toxicity</term>
                    <def id="onco12812-li-0147">
                      <p>46</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0148">Number of Patients Evaluated for Efficacy</term>
                    <def id="onco12812-li-0149">
                      <p>46</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0150">Evaluation Method</term>
                    <def id="onco12812-li-0151">
                      <p>RECIST 1.0</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0152">Response Assessment – PR</term>
                    <def id="onco12812-li-0153">
                      <p><italic>n</italic> = 5 (10.9%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0154">Response Assessment – SD</term>
                    <def id="onco12812-li-0155">
                      <p><italic>n</italic> = 24 (52.2%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0156">Response Assessment – PD</term>
                    <def id="onco12812-li-0157">
                      <p><italic>n</italic> = 12 (26.1%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0158">Response Assessment – Other</term>
                    <def id="onco12812-li-0159">
                      <p><italic>n</italic> = 5 (10.9%)</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0160">(Median) Duration Assessments – PFS</term>
                    <def id="onco12812-li-0161">
                      <p>2 months; CI, 1.8–3.3 months</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0162">(Median) Duration Assessments – OS</term>
                    <def id="onco12812-li-0163">
                      <p>4.2 months; CI, 3.5–7.8 months</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0164">Outcome Notes</term>
                    <def id="onco12812-li-0165">
                      <p>Outcomes are summarized in Table <xref rid="onco12812-tbl-0002" ref-type="table">2</xref>.</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12812-sec-0014">
              <title>Adverse Events</title>
              <p>
                <def-list list-type="simple" id="onco12812-lp-0008">
                  <def-item>
                    <term id="onco12812-li-0166">Adverse events are summarized in Table <xref rid="onco12812-tbl-0003" ref-type="table">3</xref>.</term>
                    <def id="onco12812-li-0167">
                      <p> </p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12812-sec-0015">
              <title>Assessment, Analysis, and Discussion</title>
              <p>
                <def-list list-type="simple" id="onco12812-lp-0009">
                  <def-item>
                    <term id="onco12812-li-0168">Completion</term>
                    <def id="onco12812-li-0169">
                      <p>Study completed</p>
                    </def>
                  </def-item>
                  <def-item>
                    <term id="onco12812-li-0170">Investigator's Assessment</term>
                    <def id="onco12812-li-0171">
                      <p>Level of activity did not meet planned endpoint</p>
                    </def>
                  </def-item>
                </def-list>
              </p>
            </sec>
            <sec id="onco12812-sec-2015">
              <p>Pancreatic cancer is a highly lethal malignancy, and the survival of patients with advanced disease is less than a year, ranging from 6 to 11 months in patients on clinical trials. Long‐term survivors are rare, and even among patients with surgically resected disease, the 10‐year overall survival is 3.9% [<xref rid="onco12812-bib-0006" ref-type="ref">6</xref>]. Most patients who undergo resection will suffer a recurrence within 5 years, which is invariably fatal. Adjuvant therapy improves outcomes following surgery, but even with such therapy, the outcome is poor and recurrences remain very common [<xref rid="onco12812-bib-0007" ref-type="ref">7</xref>], [<xref rid="onco12812-bib-0008" ref-type="ref">8</xref>]. Given the high recurrence rate following surgery and the fact that the majority of patients have either metastatic or locally advanced disease at diagnosis, there is a great need for better systemic therapy. Gemcitabine was the standard therapy for advanced pancreatic cancer for more than 10 years, and multiple trials combining cytotoxic or targeted therapy with gemcitabine showed no improvement over gemcitabine alone [<xref rid="onco12812-bib-0009" ref-type="ref">9</xref>].</p>
              <p>The epidermal growth factor receptor (EGFR) pathway has been considered a potential target for therapy in pancreatic cancer. Increased expression of EGFR and its epidermal growth factor ligand are detected in pancreatic cancer tissues and predict for poor prognosis [<xref rid="onco12812-bib-0010" ref-type="ref">10</xref>], [<xref rid="onco12812-bib-0011" ref-type="ref">11</xref>]. Blocking the EGFR pathway in preclinical models was shown to suppress pancreatic cancer growth, suggesting a potential therapeutic target [<xref rid="onco12812-bib-0012" ref-type="ref">12</xref>], [<xref rid="onco12812-bib-0013" ref-type="ref">13</xref>]. Dual EGFR blockage with a monoclonal antibody and a tyrosine kinase inhibitor was also shown to have effect on tumor growth, suggesting utility in patients with pancreatic cancer [<xref rid="onco12812-bib-0014" ref-type="ref">14</xref>]. <italic>KRAS</italic> mutations are very common in pancreatic cancer and may be predictive of an inferior survival, but unlike in colorectal cancer, <italic>KRAS</italic> mutations do not appear to predict outcomes in patients with pancreatic cancer treated with EGFR inhibitors [<xref rid="onco12812-bib-0015" ref-type="ref">15</xref>], [<xref rid="onco12812-bib-0016" ref-type="ref">16</xref>], [<xref rid="onco12812-bib-0017" ref-type="ref">17</xref>].</p>
              <p>The combination of gemcitabine and erlotinib showed a very modest and statistically significant prolongation of overall survival in patients with metastatic pancreatic cancer, but the clinical significance was questionable, and the combination never gained traction [<xref rid="onco12812-bib-0002" ref-type="ref">2</xref>]. It was not until 2011 that substantial improvements were made, when oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was shown to substantially prolong overall survival compared with gemcitabine alone, from 6.8 months to 11.1 months [<xref rid="onco12812-bib-0018" ref-type="ref">18</xref>]. Shortly thereafter, the combination of gemcitabine and albumin‐bound paclitaxel (nab‐paclitaxel) was shown to be superior to gemcitabine alone, prolonging the overall survival of patients from 6.7 months to 8.5 months [<xref rid="onco12812-bib-0019" ref-type="ref">19</xref>]. Gemcitabine alone is no longer considered an acceptable therapy for metastatic pancreatic cancer except for patients with impaired performance status or for patients who desire to receive less aggressive, and less toxic, albeit less effective, therapy [<xref rid="onco12812-bib-0020" ref-type="ref">20</xref>].</p>
              <p>Our trial was designed before FOLFIRINOX and gemcitabine with nab‐paclitaxel were shown to be superior to gemcitabine alone and when there was still a substantial enthusiasm for EGFR‐directed therapy. An early phase II trial of gemcitabine with cetuximab suggested a benefit of the combination indicating that EGFR was a potential target in pancreatic cancer [<xref rid="onco12812-bib-0021" ref-type="ref">21</xref>]. A National Cancer Institute of Canada phase III trial of erlotinib given with gemcitabine, an oral EGFR inhibitor, showed a statistically significant but very modest prolongation of overall survival [<xref rid="onco12812-bib-0002" ref-type="ref">2</xref>]. These findings, along with preclinical data, led to the design of our trial testing the hypothesis that two EGFR inhibitors of different classes could be superior to gemcitabine and erlotinib, a reasonable therapy standard at that time. Unfortunately, a large phase III trial (Southwest Oncology Group S0205) failed to show improvement of survival in patients treated with gemcitabine and cetuximab over gemcitabine alone [<xref rid="onco12812-bib-0003" ref-type="ref">3</xref>]. In this large trial, there was no difference in overall survival of patients among the two arms—6.3 months for the combination versus 5.9 months for gemcitabine alone (hazard ratio, 1.06; 95% confidence interval, 0.91–1.23; <italic>p</italic> = .23)—and a 2‐ week improvement was seen in the time to treatment failure (<italic>p</italic> = .006).</p>
              <p>The current trial showed a statistically significant difference observed in terms of overall survival favoring the combination of dual EGFR inhibition and gemcitabine. The dual EGFR inhibition therapy was more toxic, as expected. The relevance of this finding is of uncertain clinical significance, as gemcitabine monotherapy can no longer be considered an appropriate chemotherapy backbone for combination therapy with targeted agents given the superiority of cytotoxic doublet or triplet therapy, and toxicities, especially dermatological, were substantial. Dual EGFR inhibition may be even more challenging in conjunction with chemotherapy doublets or triplets given the adverse events seen with gemcitabine alone. Further studies of EGFR inhibitors administered concurrently with cytotoxic agents are unlikely to result in a meaningful improvement in the outcome of patients with metastatic pancreatic cancer and cannot be recommended.</p>
            </sec>
            <sec id="onco12812-sec-3013">
              <title>Figure and Tables</title>
              <table-wrap id="onco12812-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                <label>Table 1.</label>
                <caption>
                  <title>Trial and patient characteristics</title>
                </caption>
                <graphic id="nlm-graphic-5" specific-use="sourcefile-name" xlink:href="onco12812-tbl-0001">
                  <alt-text>image</alt-text>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                  </permissions>
                </graphic>
                <table-wrap-foot id="onco12812-ntgp-0001">
                  <fn id="onco12812-note-0001">
                    <p>Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap id="onco12812-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                <label>Table 2.</label>
                <caption>
                  <title>Outcomes</title>
                </caption>
                <graphic id="nlm-graphic-7" specific-use="sourcefile-name" xlink:href="onco12812-tbl-0002">
                  <alt-text>image</alt-text>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                  </permissions>
                </graphic>
              </table-wrap>
              <table-wrap id="onco12812-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                <label>Table 3.</label>
                <caption>
                  <title>Adverse events, grades 3 and 4</title>
                </caption>
                <graphic id="nlm-graphic-9" specific-use="sourcefile-name" xlink:href="onco12812-tbl-0003">
                  <alt-text>image</alt-text>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                  </permissions>
                </graphic>
                <table-wrap-foot id="onco12812-ntgp-0002">
                  <fn id="onco12812-note-0002">
                    <p>Bold <italic>p</italic> values indicate statistical significance.</p>
                  </fn>
                  <fn id="onco12812-note-0003">
                    <p>Abbreviation: ALT, alanine aminotransferase.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig fig-type="Figure" xml:lang="en" id="onco12812-fig-0002" orientation="portrait" position="float">
                <label>Figure 2.</label>
                <caption>
                  <p>Progression‐free survival by treatment arm.</p>
                  <p>Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Gem, gemcitabine.</p>
                </caption>
                <graphic id="nlm-graphic-11" specific-use="sourcefile-name" xlink:href="onco12812-fig-0002">
                  <alt-text>image</alt-text>
                </graphic>
              </fig>
            </sec>
          </body>
          <back>
            <ack id="onco12812-sec-0017">
              <title>Acknowledgments</title>
              <p>The following institutional networks participated in this study: Colorado Cancer Research Program NCORP (National Cancer Institute [NCI] Community Oncology Research Program), Denver, CO, Keren Sturtz, UG1CA189805; Dayton NCI Community Oncology Research Program, Dayton, OH, Howard Gross, UG1CA189957; Geisinger Cancer Institute NCI Community Oncology Research Program, Danville, PA, Srilatha Hosur, UG1CA189847; Hawaii Minority Underserved NCORP, Honolulu, HI, Jeffrey Berenberg, UG1CA189804; Iowa‐Wide Oncology Research Coalition NCORP, Des Moines, IA, Robert Behrens, UG1CA189816; Mayo Clinic LAPS, Rochester, MN, Steven Alberts, U10CA180790; Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, MN, Daniel Anderson, UG1CA189863; Michigan Cancer Research Consortium NCORP, Ann Arbor, MI, Philip Stella, UG1CA189971; Missouri Valley Cancer Consortium CCOP (Community Clinical Oncology Program), Omaha, NE, Gamini Soori, U10CA063849; Montana Cancer Consortium NCORP, Billings, MT, Benjamin Marchello, UG1CA189872; Northern Indiana Cancer Research Consortium, South Bend, IN; Michael Method, U10CA086726; Ochsner NCI Community Oncology Research Program, New Orleans, LA, John Cole, UG1CA189870; Pacific Cancer Research Consortium NCORP, Seattle, WA, Alison Conlin, UG1CA189953; Rapid City Regional Hospital, Rapid City, SD, Joshua Lukenbill; Sanford NCI Community Oncology Research Program of the North Central Plains, Sioux Falls, SD, Preston Steen, UG1CA189825; Southeast Clinical Oncology Research Consortium NCORP, Winston‐Salem, NC, James Atkins, UG1CA189858; Toledo Clinic Cancer Centers‐Toledo, Toledo, OH, Rex Mowat; Toledo Community Hospital Oncology Program CCOP, Toledo, OH, Rex Mowat; Wichita NCI Community Oncology Research Program, Wichita, KS, Shaker Dakhil, UG1CA189808; and Wisconsin NCI Community Oncology Research Program, Marshfield, WI, Anthony Jaslowski, UG1CA189956.</p>
            </ack>
            <fn-group id="onco12812-ntgp-0003">
              <fn fn-type="other" id="onco12812-note-1201">
                <p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT00550836">NCT00550836</ext-link></p>
                <p><bold>Sponsor(s):</bold> Alliance for Clinical Trials in Oncology</p>
                <p><bold>Principal Investigator:</bold> George P. Kim</p>
                <p><bold>IRB Approved:</bold> Yes</p>
              </fn>
              <fn id="onco12812-note-3392">
                <p><ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results">Click here to access other published clinical trials</ext-link>.</p>
              </fn>
            </fn-group>
            <sec id="onco12812-sec-0018" sec-type="disclosure">
              <title>Disclosures</title>
              <p><bold>Thorvardur R. Halfdanarson:</bold> Advanced Accelerator Applications (institutional), Lexicon (C/A), Ipsen, ThermoFisher Scientific, ArQule, Agios (institutional) (RF); <bold>George P. Kim:</bold> Genentech, Amgen (C/A, H). The other authors indicated no financial relationships.</p>
              <p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p>
            </sec>
            <ref-list id="onco12812-bibl-0001" content-type="cited-references">
              <title>References</title>
              <ref id="onco12812-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0001"><string-name><surname>Burris</surname><given-names>HA</given-names><suffix>3rd</suffix></string-name>, <string-name><surname>Moore</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>J</given-names></string-name> et al. <article-title>Improvements in survival and clinical benefit with gemcitabine as first‐line therapy for patients with advanced pancreas cancer: A randomized trial</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>1997</year>;<volume>15</volume>:<fpage>2403</fpage>–<lpage>2413</lpage>.<pub-id pub-id-type="pmid">9196156</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0002"><string-name><surname>Moore</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Goldstein</surname><given-names>D</given-names></string-name>, <string-name><surname>Hamm</surname><given-names>J</given-names></string-name> et al. <article-title>Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2007</year>;<volume>25</volume>:<fpage>1960</fpage>–<lpage>1966</lpage>.<pub-id pub-id-type="pmid">17452677</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0003"><string-name><surname>Philip</surname><given-names>PA</given-names></string-name>, <string-name><surname>Benedetti</surname><given-names>J</given-names></string-name>, <string-name><surname>Corless</surname><given-names>CL</given-names></string-name> et al. <article-title>Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group‐directed intergroup trial S0205</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2010</year>;<volume>28</volume>:<fpage>3605</fpage>–<lpage>3610</lpage>.<pub-id pub-id-type="pmid">20606093</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0004"><string-name><surname>Matar</surname><given-names>P</given-names></string-name>, <string-name><surname>Rojo</surname><given-names>F</given-names></string-name>, <string-name><surname>Cassia</surname><given-names>R</given-names></string-name> et al. <article-title>Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC‐C225): Superiority over single‐agent receptor targeting</article-title>. <source xml:lang="en">Clin Cancer Res</source>
<year>2004</year>;<volume>10</volume>:<fpage>6487</fpage>–<lpage>6501</lpage>.<pub-id pub-id-type="pmid">15475436</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0005"><string-name><surname>Baselga</surname><given-names>J</given-names></string-name>, <string-name><surname>Schöffski</surname><given-names>P</given-names></string-name>, <string-name><surname>Rojo</surname><given-names>F</given-names></string-name> et al. <article-title>A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti‐EGFR therapies, the monoclonal antibody (Mab) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non‐small cell lung cancer (NSCLC)</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2006</year>;<volume>24</volume>(<issue>suppl 18</issue>):<fpage>3006A</fpage>.</mixed-citation>
              </ref>
              <ref id="onco12812-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0006"><string-name><surname>Paniccia</surname><given-names>A</given-names></string-name>, <string-name><surname>Hosokawa</surname><given-names>P</given-names></string-name>, <string-name><surname>Henderson</surname><given-names>W</given-names></string-name> et al. <article-title>Characteristics of 10‐year survivors of pancreatic ductal adenocarcinoma</article-title>. <source xml:lang="en">JAMA Surg</source>
<year>2015</year>;<volume>150</volume>:<fpage>701</fpage>–<lpage>710</lpage>.<pub-id pub-id-type="pmid">26062046</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0007"><string-name><surname>Oettle</surname><given-names>H</given-names></string-name>, <string-name><surname>Neuhaus</surname><given-names>P</given-names></string-name>, <string-name><surname>Hochhaus</surname><given-names>A</given-names></string-name> et al. <article-title>Adjuvant chemotherapy with gemcitabine and long‐term outcomes among patients with resected pancreatic cancer: The CONKO‐001 randomized trial</article-title>. <source xml:lang="en">JAMA</source>
<year>2013</year>;<volume>310</volume>:<fpage>1473</fpage>–<lpage>1481</lpage>.<pub-id pub-id-type="pmid">24104372</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0008"><string-name><surname>Neoptolemos</surname><given-names>JP</given-names></string-name>, <string-name><surname>Palmer</surname><given-names>DH</given-names></string-name>, <string-name><surname>Ghaneh</surname><given-names>P</given-names></string-name> et al. <article-title>Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC‐4): A multicentre, open‐label, randomised, phase 3 trial</article-title>. <source xml:lang="en">Lancet</source>
<year>2017</year>;<volume>389</volume>:<fpage>1011</fpage>–<lpage>1024</lpage>.<pub-id pub-id-type="pmid">28129987</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0009"><string-name><surname>Berlin</surname><given-names>J</given-names></string-name>, <string-name><surname>Benson</surname><given-names>AB</given-names><suffix>3rd</suffix></string-name>. <article-title>Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer</article-title>. <source xml:lang="en">Nat Rev Clin Oncol</source><year>2010</year>;<volume>7</volume>:<fpage>135</fpage>–<lpage>137</lpage>.<pub-id pub-id-type="pmid">20190797</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0010"><string-name><surname>Korc</surname><given-names>M</given-names></string-name>, <string-name><surname>Chandrasekar</surname><given-names>B</given-names></string-name>, <string-name><surname>Yamanaka</surname><given-names>Y</given-names></string-name> et al. <article-title>Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha</article-title>. <source xml:lang="en">J Clin Invest</source>
<year>1992</year>;<volume>90</volume>:<fpage>1352</fpage>–<lpage>1360</lpage>.<pub-id pub-id-type="pmid">1401070</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0011"><string-name><surname>Yamanaka</surname><given-names>Y</given-names></string-name>, <string-name><surname>Friess</surname><given-names>H</given-names></string-name>, <string-name><surname>Kobrin</surname><given-names>MS</given-names></string-name> et al. <article-title>Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness</article-title>. <source xml:lang="en">Anticancer Res</source>
<year>1993</year>;<volume>13</volume>:<fpage>565</fpage>–<lpage>569</lpage>.<pub-id pub-id-type="pmid">8317885</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0012"><string-name><surname>Overholser</surname><given-names>JP</given-names></string-name>, <string-name><surname>Prewett</surname><given-names>MC</given-names></string-name>, <string-name><surname>Hooper</surname><given-names>AT</given-names></string-name> et al. <article-title>Epidermal growth factor receptor blockade by antibody IMC‐C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice</article-title>. <source xml:lang="en">Cancer</source>
<year>2000</year>;<volume>89</volume>:<fpage>74</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">10897003</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0013"><string-name><surname>Bruns</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Harbison</surname><given-names>MT</given-names></string-name>, <string-name><surname>Davis</surname><given-names>DW</given-names></string-name> et al. <article-title>Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms</article-title>. <source xml:lang="en">Clin Cancer Res</source>
<year>2000</year>;<volume>6</volume>:<fpage>1936</fpage>–<lpage>1948</lpage>.<pub-id pub-id-type="pmid">10815919</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0014"><string-name><surname>Huang</surname><given-names>S</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>EA</given-names></string-name>, <string-name><surname>Benavente</surname><given-names>S</given-names></string-name> et al. <article-title>Dual‐agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti‐EGFR antibody with tyrosine kinase inhibitor</article-title>. <source xml:lang="en">Cancer Res</source>
<year>2004</year>;<volume>64</volume>:<fpage>5355</fpage>–<lpage>5362</lpage>.<pub-id pub-id-type="pmid">15289342</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0015"><string-name><surname>Boeck</surname><given-names>S</given-names></string-name>, <string-name><surname>Jung</surname><given-names>A</given-names></string-name>, <string-name><surname>Laubender</surname><given-names>RP</given-names></string-name> et al. <article-title>KRAS mutation status is not predictive for objective response to anti‐EGFR treatment with erlotinib in patients with advanced pancreatic cancer</article-title>. <source xml:lang="en">J Gastroenterol</source>
<year>2013</year>;<volume>48</volume>:<fpage>544</fpage>–<lpage>548</lpage>.<pub-id pub-id-type="pmid">23435671</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0016"><string-name><surname>Haas</surname><given-names>M</given-names></string-name>, <string-name><surname>Ormanns</surname><given-names>S</given-names></string-name>, <string-name><surname>Baechmann</surname><given-names>S</given-names></string-name> et al. <article-title>Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer</article-title>. <source xml:lang="en">Br J Cancer</source>
<year>2017</year>;<volume>116</volume>:<fpage>1462</fpage>–<lpage>1469</lpage>.<pub-id pub-id-type="pmid">28449008</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0017"><string-name><surname>Tao</surname><given-names>LY</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>LF</given-names></string-name>, <string-name><surname>Xiu</surname><given-names>DR</given-names></string-name> et al. <article-title>Prognostic significance of K‐ras mutations in pancreatic cancer: A meta‐analysis</article-title>. <source xml:lang="en">World J Surg Oncol</source>
<year>2016</year>;<volume>14</volume>:<fpage>146</fpage>.<pub-id pub-id-type="pmid">27183870</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0018"><string-name><surname>Conroy</surname><given-names>T</given-names></string-name>, <string-name><surname>Desseigne</surname><given-names>F</given-names></string-name>, <string-name><surname>Ychou</surname><given-names>M</given-names></string-name> et al. <article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2011</year>;<volume>364</volume>:<fpage>1817</fpage>–<lpage>1825</lpage>.<pub-id pub-id-type="pmid">21561347</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0019"><string-name><surname>Von Hoff</surname><given-names>DD</given-names></string-name>, <string-name><surname>Ervin</surname><given-names>T</given-names></string-name>, <string-name><surname>Arena</surname><given-names>FP</given-names></string-name> et al. <article-title>Increased survival in pancreatic cancer with nab‐paclitaxel plus gemcitabine</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2013</year>;<volume>369</volume>:<fpage>1691</fpage>–<lpage>1703</lpage>.<pub-id pub-id-type="pmid">24131140</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0020"><string-name><surname>Sohal</surname><given-names>DP</given-names></string-name>, <string-name><surname>Mangu</surname><given-names>PB</given-names></string-name>, <string-name><surname>Khorana</surname><given-names>AA</given-names></string-name> et al. <article-title>Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2016</year>;<volume>34</volume>:<fpage>2784</fpage>–<lpage>2796</lpage>.<pub-id pub-id-type="pmid">27247222</pub-id></mixed-citation>
              </ref>
              <ref id="onco12812-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="onco12812-cit-0021"><string-name><surname>Xiong</surname><given-names>HQ</given-names></string-name>, <string-name><surname>Rosenberg</surname><given-names>A</given-names></string-name>, <string-name><surname>LoBuglio</surname><given-names>A</given-names></string-name> et al. <article-title>Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2004</year>;<volume>22</volume>:<fpage>2610</fpage>–<lpage>2616</lpage>.<pub-id pub-id-type="pmid">15226328</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
